Table 1. Basic clinical data for the patients whose liver tissues were submitted for fibrosis evaluation.
| Training cohort | Verification cohort | |
|---|---|---|
| n = 105 | n = 70 | |
| Age (years) | 45.7 ± 11.8 | 44.0 ± 11.2 |
| Male, n (%) | 85 (83.3) | 59 (84.3) |
| Biopsy | ||
| Necroinflammation score | ||
| Periportal inflammation | 1.2 ± 0.7 | 0.9 ± 0.9 |
| Confluence necrosis | 0.1 ± 0.5 | 0.2 ± 0.9 |
| Focal inflammation | 2.0 ± 0.7 | 2.0 ± 0.8 |
| Portal inflammation | 2.4 ± 0.9 | 2.2 ± 1.0 |
| ISHAK fibrosis score, n (%) | ||
| 1 | 12 (11.4) | 10 (14.3) |
| 2 | 19 (18.1) | 12 (17.1) |
| 3 | 27 (25.7) | 24 (34.3) |
| 4 | 15 (14.3) | 10 (14.3) |
| 5 | 22 (21.0) | 11 (15.7) |
| 6 | 10 (9.5) | 3 (4.3) |
| HBeAg-positive, n (%) | 37(52.1) | 31 (63.3) |
| Biochemistry | ||
| AST (IU/mL) | 117.0 ± 92.0 | 92.6 ± 120.7 |
| ALT (IU/mL) | 220.9 ± 201.1 | 162.9 ± 202.5 |
| AST/ALT | 0.6 ± 0.4 | 0.6 ± 0.3 |
| AFP (ng/mL) | 10.5 ± 26.7 | 13.2 ± 65.7 |
| Bilirubin (mg/dL) | 1.1 ± 0.7 | 1.0 ± 0.4 |
| GGT (IU/L) | 80.4 ± 94.7 | 49.9 ± 43.6 |
| Albumin (g/dL) | 4.6 ± 0.3 | 4.5 ± 0.4 |
| Platelets (×1000/mm3) | 185.5 ± 58.0 | 189.8 ± 55.0 |
| Prothrombin time prolongation (sec) | 0.7 ± 0.6 | 1 ± 0.9 |
| White blood cells (×1000/mm3) | 5.6 ± 1.8 | 5.4 ± 1.5 |
| Hemoglobin (g/dL) | 15.0 ± 1.5 | 14.9 ± 1.5 |
| Alpha-1 globulin (g/dL) | 0.2 ± 0.1 | 0.2 ± 0.1 |
| Alpha-2 globulin (g/dL) | 0.8 ± 0.2 | 0.8 ± 0.1 |
| Beta globulin (g/dL) | 0.8 ± 0.2 | 0.8 ± 0.1 |
| Gamma globulin (g/dL) | 1.6 ± 0.4 | 1.5 ± 0.5 |
| Albumin/globulin | 1.5 ± 0.3 | 1.5 ± 0.4 |